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should take caution when mapping EQ-5D values from algorithms that have not 
been externally validated, especially where these algorithms have used clinical 
outcomes or disease-specific measures of health-related quality of life. Our results 
suggest that mapping from generic outcome measures might be reasonable.
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Objectives: The Mini-International Neuropsychiatric Interview (M.I.N.I.) is a short, 
structured diagnostic interview, developed by psychiatrists and clinicians in the 
USA and Europe, for DSM-IV and ICD-10 psychiatric disorders. The objectives of our 
study were: 1) To determine if the psychiatric terms used in the M.I.N.I. are trans-
latable worldwide, especially in non-western countries, and 2) To review strategies 
used to culturally adapt psychiatric terms. MethOds: We reviewed the records 
of all linguistic validation projects involving the M.I.N.I. Results: We retrieved 
67 language versions, representing 47 countries. The analysis of the translations’ 
content revealed three types of results, depending on the existence (or not) of cor-
responding psychiatric terminology in the target languages. The standard meth-
odology (forward/backward and clinician review) was used in all countries and 
adapted, depending on the context. In all western and westernized countries (e.g., 
Europe, Russia, etc., totaling 49 languages), the psychiatric terms used in the M.I.N.I. 
were easily translated (i.e., existence of an agreed-upon corresponding terminol-
ogy). In languages where psychiatric terms do not exist (e.g., certain Sub-Saharan 
languages), all the clinician-directed parts (titles and clinician-directed instruc-
tions/algorithms), which are capitalized in the original instrument, were left in 
English, and the patient-directed parts were translated in the target languages. In 
languages where there is a partially agreed-upon terminology (e.g., Thai), the titles 
as well as the algorithms were translated with corresponding English equivalents 
between brackets, when necessary. Moreover, in order to follow the typographical 
conventions of the M.I.N.I., in languages with no capital letters (such as Kannada 
or Malayalam), the translations used bigger font size. cOnclusiOns: This review 
showed that terms used to describe psychiatric disorders had no equivalents in 
some countries, especially in Africa. Translation was not always possible and was 
even judged to be culturally and linguistically irrelevant in countries where psy-
chiatry is only taught in English.
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Objectives: Sawicki questionnaire is a 32-item specific measure for the evalu-
ation of the change in the measure of the Quality of Health Related Life (HRQOL) 
experienced by patients treated by Novel Oral Anticoagulants (NOACs) versus tra-
ditional Oral Anticoagulant Therapies (OAT). The objective of this research focuses 
on the application of the Rasch model in selecting the most appropriate items of 
Sawicki questionnaire. MethOds: Sample was composed of 689 Atrial Fibrillation 
(AF) patients in whom an attempt of electrical or pharmacological cardioversion 
was scheduled within a 4 months inclusion period from baseline (CARDIOVERSE 
study). Data were analyzed with WinSteps version 3.75 using the Rasch Partial 
Credit Model. Statistical criteria taken into account for the selection of those 
items with better psychometric properties were: model-fit and separation statis-
tics, Differential Item Functioning (DIF), unexpected responses and item content. 
The results were compared with those of the original version of the question-
naire in CARDIOVERSE sample. Results: Misfiting items were deleted, resulting in 
a 12 items version rated on a 4-point Likert-scale. This short form of the ques-
tionnaire showed good model fit and represented an accurate measure of the 
construct. Infit MNSQ ranged from 0.90 to 1.15 (M= 1.02; SD= 0.09) and outfit MNSQ 
ranged from 0.90 to 1.18 (M= 1.02; SD= 0.08). Person separation index and item 
reliability were 2.11 and 0.99 respectively and item-person map showed that the 
test was on-target and covered the wide range of the ability scale. Finally, the 
criterion validity of the short version by age, sex and risk groups was similar to 
the original version of the questionnaire. cOnclusiOns: Short version of Sawicki 
questionnaire has adequate psychometric properties in terms of goodness-of-
fit-test and reliability. This version makes it possible to have a new short and 
appropriate HRQoL measure for the study of the effect in QoL experienced by 
patients treated by NOACs.
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Objectives: To test convergent-discriminant validity of quality of life (QOL) 
impact attributions to arthritis and respiratory conditions using the multitrait-
multimethod (MTMM) approach. MethOds: Chronically-ill adults (N= 601) with 
osteoarthritis (OA) and respiratory (asthma, COPD) disease completed Internet-
based surveys. Ages ranged from 18-93 (median= 58), 66.5% female and 20.7% non-
white. QOL impact was measured using 3 methods: QOL Disease Impact Scale 
(QDIS) and disease severity with specific attribution to each condition, specific 
worse cognitive function. Fifteen items had responses with ≥ 35% frequency and 
three items (turning a key, recreational activities with force, recreational activities 
with moving arm freely) had responses with ≥ 50% frequency. cOnclusiOns: 
Patients had no complaints about understanding or difficulty of the adapted ver-
sion of the questionnaire. Still, there were some items with missing answers (most 
often - sexual activity). Although, we provide some evidence of content validity, 
additional testing for the retention of psychometric properties of the translated 
questionnaire is recommended.
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Objectives: For models that simulate patients over a long span, such as from birth 
to life expectancy, the baseline HRQoL can be incorporated. Typically this means 
that younger people have a higher utility than older people. The aim of this study 
was to investigate the impact of including age-specific baseline utilities in a model 
that simulated women at elevated risk of developing breast cancer from ages 20 to 
85. MethOds: A model was developed to evaluate the impact on costs and benefits 
of breast cancer surveillance in a population of women with a BRCA1 mutation. 
Women were modelled from age 20 to 85. QALY reductions were associated with the 
treatment of cancer and were stage-specific. The model was evaluated incorporat-
ing age-specific baseline QALYs and also where all ages had a baseline QALY of 1. 
The impact of age-specific baseline QALY inclusion was evaluated in terms of the 
ICERs for different surveillance strategies. Results: The incremental cost of each 
intervention and the interventions included in the cost-effectiveness efficiency 
frontier were unaffected by the choice of baseline HRQoL. However, both the average 
and incremental cost-effectiveness ratios were changed. For interventions on the 
cost-effectiveness efficiency frontier, all ICERs were less than € 100,000/QALY when 
age-specific baseline HRQoL values were used. ICERs reduced by an average € 11,520 
when a uniform baseline HRQoL was used. cOnclusiOns: The use of age-specific 
baseline HRQoL in a cost-effectiveness model needs to be carefully considered. 
Inclusion of age-specific baseline HRQoL can favour interventions with an impact 
at a younger age. Whether age-specific or uniform baseline data are used in a model, 
the alternative should be considered in a sensitivity analysis.
PRM137
eQ-5d-5L cRosswaLk vaLue set foR PoLand
Golicki D., Niewada M.
Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, 
Poland
Objectives: To estimate EQ-5D-5L crosswalk value set for Poland, based on 
Crosswalk methodology developed by EuroQol Group. MethOds: Based on the data 
from 3691 respondents from 6 European countries, EuroQol Group has developed 
a method of obtaining interim values sets for the EQ-5D-5L by means of map-
ping to the available EQ-5D-3L values sets (“crosswalk” methodology). A significant 
part of the data in this study came from Polish respondents (n= 972; 26.3%). Poland 
is the first Central European country with EQ-5D-3L time trade-off based social 
values set published. In order to obtain interim EQ-5D-5L values set, we applied 
Crosswalk methodology, developed by EuroQol Group, to available Polish EQ-5D-3L 
values set. Results: Estimated Polish values for 3125 EQ-5D-5L health states will 
be presented. Both, EQ-5D-5L and EQ-5D-3L values sets have the same range (from 
-0.523 to 1.000), but different means (0.448 vs. 0.380) and medians (0.483 vs. 0.403), 
respectively. Participation of states worse than dead is less in EQ-5D-5L (5.38%), 
than in EQ-5D-3L (13.17%) values set. cOnclusiOns: As long as value set based on 
preferences directly elicited from representative Polish general population sample 
is not available, estimated crosswalk values set should be used in EQ-5D-5L studies 
in Poland in order to calculate health state utilities.
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Objectives: Existing studies exploring the validity of using mapping algorithms 
to predict utilities in external datasets have found mixed results. We apply a series 
of published EQ-5D mapping algorithms to individual patient level data from a 
trial which in fact collected this outcome, with a view to assess the impact of 
using predicted versus actual EQ-5D values on the results of a cost-effectiveness 
model. MethOds: The RITA-3 trial compared early interventional strategy for 
patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) against 
a conservative strategy. EQ-5D data were collected at baseline, 4 months, 12 
months and yearly thereafter. A range of other clinical and quality of life out-
comes were also collected including the Seattle Angina Questionnaire (SAQ), 
SF-36 and the Canadian Cardiovascular Society (CCS) Functional Classification of 
Angina. Using mapping algorithms found in the published literature, we predicted 
EQ-5D scores using these outcome measures. We then explored what effect the 
predicted utilities had upon cost-effectiveness estimates in a model compared 
to those with the actual EQ-5D data. The comparisons were made across five 
patient subgroups. Results: The cost-effectiveness estimates varied according to 
the original outcome measure used to map and the patient subgroup. The EQ-5D 
values predicted using CCS scores produced cost-effectiveness estimates much 
higher than those with the actual EQ-5D data in the trial, whilst the estimates 
using EQ-5D values predicted using SAQ scores were lower. The values predicted 
using SF-36 scores gave cost-effectiveness estimates very similar to those with 
the EQ-5D data, irrespective of the patient subgroup. cOnclusiOns: Analysts 
